Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND AND AIMS: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis.
METHODS: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram.
RESULTS: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% at 12-, 24- and 36-months from end-of-therapy, respectively (incidence rate 2.45/100 person-years). Age, genotype 3, diabetes, platelets (PLT)≤120,000/µl and albumin ≤3.5g/dl levels were identified as pre-treatment HCC independent predictors. Adjusting for age, the post-treatment PLT≤120,000/µl (AdjHR 1.92; 95%CI:1.06-3.45) and albumin≤3.5g/dl (AdjHR 4.38; 95%CI 2.48-7.75) values were independently associated with HCC occurrence. Two different risk profiles were identified by combining long-term post-therapy evaluation of PLT ≤ vs. >120,000/µl and albumin ≤ vs. >3.5g/dl showing a significant different HCC incidence rate of 1.35 vs. 3.77/100 p-y, respectively.
CONCLUSIONS: The nomogram score based on age, PLT and albumin levels after SVR showed an accurate prediction capability and may support the customizing management for early HCC detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 55(2023), 7 vom: 01. Juli, Seite 907-917 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kondili, Loreta A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 30.06.2023 Date Revised 21.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2023.01.153 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352851163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352851163 | ||
| 003 | DE-627 | ||
| 005 | 20231226054652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2023.01.153 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352851163 | ||
| 035 | |a (NLM)36775720 | ||
| 035 | |a (PII)S1590-8658(23)00164-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kondili, Loreta A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2023 | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis | ||
| 520 | |a METHODS: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram | ||
| 520 | |a RESULTS: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% at 12-, 24- and 36-months from end-of-therapy, respectively (incidence rate 2.45/100 person-years). Age, genotype 3, diabetes, platelets (PLT)≤120,000/µl and albumin ≤3.5g/dl levels were identified as pre-treatment HCC independent predictors. Adjusting for age, the post-treatment PLT≤120,000/µl (AdjHR 1.92; 95%CI:1.06-3.45) and albumin≤3.5g/dl (AdjHR 4.38; 95%CI 2.48-7.75) values were independently associated with HCC occurrence. Two different risk profiles were identified by combining long-term post-therapy evaluation of PLT ≤ vs. >120,000/µl and albumin ≤ vs. >3.5g/dl showing a significant different HCC incidence rate of 1.35 vs. 3.77/100 p-y, respectively | ||
| 520 | |a CONCLUSIONS: The nomogram score based on age, PLT and albumin levels after SVR showed an accurate prediction capability and may support the customizing management for early HCC detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Direct-acting antiviral | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a Long term outcomes | |
| 650 | 4 | |a Predictive factors | |
| 650 | 4 | |a Real-life cohort | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Quaranta, Maria Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalletto, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Calvaruso, Vincenza |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrigno, Luigina |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ambrosio, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Simonelli, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Brancaccio, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Raimondo, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetto, Maurizia R |e verfasserin |4 aut | |
| 700 | 1 | |a Zignego, Anna Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Biliotti, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Verucchi, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Massari, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Licata, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Barbaro, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Persico, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Francesco Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Morisco, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Pompili, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Viganò, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Puoti, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Santantonio, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Villa, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Craxì, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Chemello, Liliana |e verfasserin |4 aut | |
| 700 | 0 | |a PITER Collaborating Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Panetta, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Gaeta, Giovanni Battista |e investigator |4 oth | |
| 700 | 1 | |a Filomia, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Coco, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Monti, Monica |e investigator |4 oth | |
| 700 | 1 | |a Amoruso, Daniela Caterina |e investigator |4 oth | |
| 700 | 1 | |a Madonia, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Ieluzzi, Donatella |e investigator |4 oth | |
| 700 | 1 | |a Taliani, Gloria |e investigator |4 oth | |
| 700 | 1 | |a Badia, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Migliorino, Guglielmo Marco |e investigator |4 oth | |
| 700 | 1 | |a Giorgini, Alessia |e investigator |4 oth | |
| 700 | 1 | |a Masarone, Mario |e investigator |4 oth | |
| 700 | 1 | |a Blanc, Pierluigi |e investigator |4 oth | |
| 700 | 1 | |a Cossiga, Valentina |e investigator |4 oth | |
| 700 | 1 | |a De Siena, Martina |e investigator |4 oth | |
| 700 | 1 | |a Tata, Xhimi |e investigator |4 oth | |
| 700 | 1 | |a Rumi, Maria Grazia |e investigator |4 oth | |
| 700 | 1 | |a Chessa, Luchino |e investigator |4 oth | |
| 700 | 1 | |a Lampertico, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Ferrari, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Gentile, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Parruti, Giustino |e investigator |4 oth | |
| 700 | 1 | |a Baiocchi, Leonardo |e investigator |4 oth | |
| 700 | 1 | |a Ciancio, Alessia |e investigator |4 oth | |
| 700 | 1 | |a Invernizzi, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Federico, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Torti, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Morsica, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Andreone, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Aghemo, Alessio |e investigator |4 oth | |
| 700 | 1 | |a Popoli, Patrizia |e investigator |4 oth | |
| 700 | 1 | |a Vella, Stefano |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 55(2023), 7 vom: 01. Juli, Seite 907-917 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:907-917 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2023.01.153 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 7 |b 01 |c 07 |h 907-917 | ||